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Abstract
Purpose Alkylphosphocholines represent a new class of
cytostatic drugs with a novel mode of action. Erufosine
(ErPC3), the ﬁrst compound of this class that can be
administered intravenously, has recently been shown to be
active against human tumor and leukemic cell lines.
Methods In order to evaluate the antileukemic potential
of ErPC3 in acute myeloid leukemia (AML) the lethal
concentration 50% (LC 50) was determined using WST-1
assay. For analysis of cell death, staining for Annexin V
and activated caspase 3 was performed. An interaction
analysis was performed by calculation of combination
index and construction of isobolograms.
Results The LC 50 was 7.4 lg/ml after 24 h and 3.2 lg/
ml after 72 h in HL 60 cells and 30.1 and 8.6 lg/ml,
respectively, in 19 fresh samples from patients with AML.
ErPC3 was found to be cytotoxic in HL60 cells with distinct
activation of caspase 3. ErPC3 was not cross-resistant with
cytarabine, idarubicine and etoposide as shown by the linear
relation of respective LC 50s. The latter agents, however,
exerted an additive cytotoxicity in combination with ErPC3
as revealed by isobologram analysis and combination index,
although results are uneven for idarubicine.
Conclusion Based on these data ErPC3 appears as a novel
antileukemic candidate drug, which needs to be explored
further in the treatment of AML.
Keywords AML   Alkylphosphocholine   Cytarabine  
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Introduction
The combination of cytarabine with an anthracycline has
remained the therapeutic standard in the treatment of acute
myeloid leukemia (AML) for over three decades. The
improvements in remission rate and long-term survivors
achieved during that time were due to an intensiﬁcation of
therapy and improvements of supportive therapy. Clearly
there is a need for new promising antileukemic agents.
Alkylphosphocholines represent a new class of lipo-
philic drugs that interact with the cell membrane [16, 18,
27], the so called ‘‘membrane active lipids’’. They also
modulate intracellular signal transduction pathways. Their
exact mechanism of action still remains to be elucidated in
detail. To date they have been shown to exert apoptosis in
many cancer models [9, 16] and also leukemic cell lines [7,
14, 15]. Various interactions with intracellular signaling
have been found, e.g., activation of c-myc [20] and inhi-
bition of MAPK [23] and PI3K/Akt survival pathways [24].
As cytarabine in its active form as Ara-CDP choline is
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13], it could resemble a very interesting combination
partner for erufosine.
The class of alkylphosphocholines comprises various
compounds, from which only one, hexadecylphosphocho-
line (miltefosine, HePC) has been introduced into clinical
practice. HePC can be used topically for local control
of skin metastases of breast cancer [17] and orally for
eradication of visceral leishmaniasis [10]. The major dis-
advantage of this class of compounds is their poor
gastrointestinal tolerability after oral application leading to
insufﬁcient plasma levels for systemic cancer treatment.
An intravenous application of micelle-forming HePC and
analogue alkylphosphocholines is impossible due to intra-
vascular hemolysis. In addition, the recent experience with
alkylphosphocholines as drugs in the treatment of cancer
and leishmaniasis clearly demonstrated that the use of
saturated alkyl chains results in a narrow therapeutic index.
More favored and superior are alkylphosphocholines
with one cis-double bond in the alkyl chain, for instance
oleoylphosphocholine and erucylphosphocholine. These
compounds have better efﬁcacy and a much larger safety
margin [1, 25].
One prototype of alkylphosphocholines with cis-double
bond is erucylphosphohomocholine (erufosine, ErPC3),
which has been shown to be applicable intravenously in
animals with a high efﬁcacy against tumor models in ani-
mals and various tumor or leukemic cell lines in vitro [7, 9].
The present study investigated the antileukemic poten-
tial of erufosine in AML in vitro both in leukemic cells
lines and fresh patient samples. In addition, the mode of
action of erufosine in AML and possible synergisms with
the most commonly used drugs cytarabine, idarubicine (as
an example for anthracyclines) and etoposide (as topoiso-
merase II inhibitor) were investigated.
Patients and methods
Patients and cell culture
Samples from adult patients (‡18 years) with ﬁrst diagnosis
of AML were included into this study. Diagnosis was based
on cell morphology according to FAB criteria comple-
mented by cytochemistry and immunophenotyping. A bone
marrow inﬁltration of[70% and collection of a sufﬁcient
number of bone marrow cells ([10
8 cells) during the initial
diagnostic bone marrow aspiration was required. The
conduct of the study was performed in accordance with the
Declaration of Helsinki and was approved by the local
ethics committee. All patients were informed of the
investigational nature of the study and gave their informed
consent.
Leukemic blasts were collected by bone marrow aspi-
ration and subsequently subjected to Ficoll hypaque
centrifugation. Prior studies have shown that following
Ficoll hypaque centrifugation purity [90% of leukemic
blasts can be obtained. Cells were diluted to a concentra-
tion of 1 · 10
7 cells/ml in Iscove’s Modiﬁed Dulbecco’s
Medium (IMDM), which was supplemented with 20 mM
HEPES, 100 lg/ml streptomycin, 10 mM L-glutamine and
10% FCS. Cultures were kept at 37 C, 5% CO2 and 95%
humidity. Before incubation viability was checked by try-
pan blue exclusion test and only samples with a viability
exceeding 80% were accepted for subsequent experiments.
Blasts from the HL 60 cell line were processed in analogy
for some of the experiments.
Drugs and media
Erufosine was kindly provided by H. Eibl and L. Lindner.
Cytarabine (AraC) was obtained from CellPharm (Han-
nover, Germany), idarubicine was from Pharmacia
(Karlsruhe, Germany) and etoposide was from Hexal
(Holzkirchen, Germany). Cell culture medium (IMDM),
PBS, HEPES, streptomycin, L-glutamine and fetal calf
serum were purchased from Gibco Life Technologies
(Eggenstein, Germany). WST-1 reagent was available from
Roche Diagnostics (Mannheim, Germany). An OPTImax
ELISA reader by Molecular Devices (Munich, Germany)
was used.
Determination of LC 50
The overall viability of cell samples was measured by the
WST-1 assay. Brieﬂy this assay is based on the cleavage of
the tetrazolium salt WST-1 to a (colored) formazan dye by
mitochondrial dehydrogenases of viable cells. The signal
can be detected spectrophotometrically in an ELISA reader
and directly correlates to the number of viable and meta-
bolically active cells in the sample. The assay was
performed in 96-well plates with 100 llo fa1 0
6 AML
blasts/ml suspension.
Following drug exposure with increasing concentrations
(ErPC3: 0.5–100 lg/ml, AraC: 0.1–100 lg/ml, idarubi-
cine: 0.1–1 lg/ml, etoposide: 0.1–50 lg/ml) for exposure
times of 24 up to 96 h 10 ll of WST-1 reagent were added
to the 100 ll cell suspension for a further incubation of 4 h.
The ELISA reader was set at a wavelength of 450 nm with
a reference wavelength of 690 nm. The results following
drug exposure were calculated as a percentage relative to
untreated controls and plotted in semi-logarithmic dose-
effect curves. Using these data points a curve was ﬁtted
(4-parameter ﬁt: y ={ ( A – D)/[1 + (x/C)
B]+D}[ 19],
322 Cancer Chemother Pharmacol (2008) 62:321–329
123which was then used to interpolate the LC 50 (the—
hypothetical—concentration that would reduce the viabil-
ity of the cell population to 50% as compared to the
untreated control).
Determination of concentration coefﬁcient N
The concept of the concentration coefﬁcient N is described
in detail elsewhere [4]. In brief, it is based on the ﬁnding
that the equation C · T = constant (C = concentration of
drug, T = exposure time of the drug) is not sufﬁcient to
describe the pharmacodynamic relationship between both
parameters for several cytotoxic agents (e.g., cytarabine) to
achieve a certain cell kill. Therefore, the concentration is
modiﬁed with an index N, resulting in the equation
C
N · T = constant. When N =1 , C and tT are equally
important in achieving a certain effect, e.g., LC 50. When
N[1, C is more important for a drug than T, i.e., that
halving C cannot be compensated by doubling T. N\1i s
found for drugs that are dependent on long exposure times
rather than on high concentrations. The detailed method to
determine N has been described by our group recently
[4, 6]. In brief, double logarithmic transformation of a
time/concentration isoeffective analysis results in a linear
relationship from which the parameter N can be extracted
as the negative gradient.
FACS analysis for detection of apoptosis
The cells from the HL 60 cell line were incubated at a
concentration of 10
6 cells/ml for 78 h and then exposed to
50 lg/ml of ErPC3 for 4 h. The cells were then washed
with ice-cold PBS buffer. For Annexin V staining, a
commercially available kit by Becton Dickinson was used.
In brief, the cells were washed twice in ice-cold PBS buffer
and diluted tenfold. The cells were then stained with
Phycoerythrin (PE) conjugated antibodies against Annexin
V and counterstained with 7-Amino-actinomycin D
(7-AAD, a color dye enriched in dead cells). After incu-
bation for 15 min in the dark at room temperature, cells
were diluted with 300 ll buffer and then measured without
gating within 1 h with FACSCalibur with CellQuest soft-
ware (Becton Dickinson, Heidelberg, Germany) on an
Apple Macintosh computer.
In addition, the active caspase 3 kit from Becton Dick-
inson was used. In brief, after exposure to ErPC3 as
mentioned above the cells were ﬁxed and permeabilized
with the Cytoﬁx/Perm Puffer provided within the kit for
30 min on ice. The cells were then washed twice and
diluted tenfold. Staining was performed with PE conju-
gated anti-caspase 3 antibodies at 4 C in the dark for
20 min. Afterwards, the cells were washed and measured
as mentioned above. All experiments were performed in
triplicate.
Interaction analysis
For interaction analysis ﬁxed ratios of combinations as
determined by the relationship of the respective LC 50s in
ng/ml determined in HL60 cells [erufosine : AraC = 1:0.2
(molar relationship 1:0.42), erufosine:idarubicine =
1:0.0025 (molar relationship 1:0.003) and erufosine:eto-
poside = 1:0.2 (molar relationship 1:0.17)] were used. The
combination index (CI) was calculated according to the
following formula [12]:
CI ¼
CcX
CiX
þ
CcY
CiY
þ a
CcX ðÞ CcY ðÞ
CiX ðÞ CiY ðÞ
where CcX is the LC 50 of drug X in combination with
drug Y, CiX is the individual LC 50 of drug X, CcY the LC
50 of drug Y in combination with drug X and CiY is the
individual LC 50 of drug Y; a = 1 or 0 depending on
whether both drugs are assumed to be mutually nonex-
clusive or mutually exclusive in their action respectively.
According to this method, synergy is assumed when the CI
is less than 1, additivity when the CI equals 1 and antag-
onism by a CI greater than 1.
For isobologram analysis, we used the method of Steel
and Peckham [26], modiﬁed by Kano et al. [11]. For
detailed description and theoretical background, please
refer to these publications. In brief, the isobologram shows
the relationship of the dose of drugs X and Y to achieve a
certain effect, in this case LC 50. From the two individual
LC 50s derived by dose-response curves and the calcula-
tion of Mode I and Mode II lines (see below), the so-called
‘‘envelope of additivity’’ can be drawn (see Fig. 1). The
measured LC 50s of the combination of both drugs falling
in this area are assumed to be additive to each other
(example point A), combinations falling below are
assumed to be supra-additive (example point B) while
combination values above the envelope are assumed to be
sub-additive (example point C). The combination points
above the square deﬁned by both individual LC 50s are
deﬁned to be protective, i.e., antagonistic (example point
D). Note that not absolute concentrations but relative val-
ues were used for the calculation.
Mode I line
When the dose of drug X is chosen there remains an
increment in effect to be produced by drug Y. If two drugs
were to act independently, the addition is performed by
Cancer Chemother Pharmacol (2008) 62:321–329 323
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survivals, which add up to LC 50.
Mode IIa line
When the dose of drug X is chosen, an isoeffect curve can
also be calculated by taking the dose increment of drug Y
that gives the required contribution to the total effect up to
the limit, in this case LC 50.
Mode IIb line
Similar as mode IIa for drug Y.
Results
Patients’ characteristics
Samples of 19 patients with AML were examined. Median
age was 62.5 years (40–84 years) with 15 male and 4
female patients. Distribution of FAB subtypes was as fol-
lows: M0 three patients, M1 four patients, M2 seven
patients, M4 four patients and M5 one patient. Unfavorable
karyotypes were seen in eight patients and normal karyo-
types and those with unknown signiﬁcance were observed
in ﬁve patients. In six patients, no karyotype was
assessable. Classiﬁcation in prognostic subgroups was
performed as follows: favorable [inv(16), t(8;21), t(15;17)],
unfavorable [–7, –5, 5q-, 7q-, inv(3), aberrations involving
11q23 and complex aberrations (three or more numerical or
structural aberrations without involvement of prognostic
favorable aberrations)], normal [46 (XY), 46 (XX)] and
unknown signiﬁcance [all others].
Determination of LC 50 and concentration coefﬁcient
in HL 60 and AML blasts
HL 60 cells
We determined the mean LC 50 of ErPC3 in HL 60 cells
after 24 h exposure to ErPC3 as 7.0 lg/ml (median 6.6 lg/
ml, range 4.0–11.0). The respective mean LC 50 after 72 h
was 3.2 lg/ml (median 3.2 lg/ml, range 2.1–4.3). A typi-
cal example of one experiment is shown in Fig. 2. The
mean LC 50 for cytarabine was 2.0 lg/ml after 24 h and
0.8 lg/ml after 72 h. For idarubicine, values of LC 50 were
0.02 and 0.004 ng/ml and for etoposide 2.8 and 0.4 ng/ml,
respectively.
According to the equation given in the section ’’Patients
and methods’’ the concentration coefﬁcient N was therefore
calculated as a mean of 1.9 (median 1.4).
Patient samples
The median LC 50 of ErPC3 in freshly collected blasts
from patients with AML was determined as 30.1 lg/ml
(mean 29.2 lg/ml, range 10.7–60.9) after 24 h exposition.
The respective median LC 50 after 96 h was 8.6 lg/ml
(mean 8.9 lg/ml, range 0.6–16.7). For cytarabine, the
mean LC 50 was 20.7 lg/ml after 24 h and 0.6 lg/ml after
96 h. For idarubicine, values of LC 50 were 1.7 and 0.9 ng/
ml and for etoposide 34.6 and 14.0 ng/ml, respectively.
Fig. 1 Schema of isobologram analysis (for detailed information
refer to text). The grey area enclosed by Mode I and Mode IIb line
deﬁnes the envelope of additivity. Point A represents an additive
combination of drug X and drug Y. Combinations (point B) falling
under this area are supraadditive, combinations above subadditive
(point C). Combinations beyond the square deﬁned by LC 50s of
individual drug X and drug Y values are considered to be protective
(or antagonistic, point D)
Fig. 2 Example of WST-1 assay in HL 60 cells after 24 h exposure
to ErPC3. Dots represent the relative survival according to an
untreated control at a certain concentration of ErPC3. From the
resulting line, the LC 50 can be extracted
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lated individually for each sample, and then the median
value was calculated from these data. N was therefore
deﬁned as 1.2 (mean 2.7, range 0.4–11.4)—implicating a
similar relevance of both concentration C and exposure
time T for the cytotoxic effect.
Analysis of cytotoxicity of ErPC3 in HL 60 cells
To characterize the mode of cell death inﬂicted by ErPC3,
we used FACS analysis in HL 60 cells exposed to ErPC3.
Only cells that stained positive for Annexin V and negative
for 7-AAD were analyzed by 4-quadrant-statistics. This
fraction represents cells in the early stage of apoptosis. The
endogenous apoptotic fraction in HL 60 cells as shown by a
positive staining for Annexin V [mean 21.4% (median
20.0%)] was signiﬁcantly raised by co-exposure to ErPC3.
After 4 h exposure to ErPC3, the apoptotic fraction was
signiﬁcantly (P\0.05) increased 4.5-fold to a mean of
97.7% (median 97.6). Figure 3a (endogenous apoptosis)
and Fig. 3b (apoptosis after 4-h exposure to ErPC3) show
representative examples.
For further analysis of cell death, the number of cells
with activated caspase 3 as one relevant inductor of clas-
sical apoptosis was measured. A mean of 10.9% (median
11.5%) of HL 60 cells stained positive for endogenous
activated forms of caspase 3, and this fraction was
signiﬁcantly doubled (P = 0.02) by a 4-h exposure to
ErPC3 (mean 21.8%, median 21.5%). Figure 3c (endoge-
nous activation of caspase 3) and Fig. 3d (after 4-h
exposure with ErPC3) are showing histogram plots of
FACS analysis of one representative experiment.
Analysis of synergy of ErPC3 with drugs in HL 60 cells
and AML samples
Cross-resistance
For detection of cross-resistance, the logarithmic values of
the respective LC 50s (ErPC3 and cytarabine, idarubicine
and etoposide) obtained in each individual experiment
were correlated (Pearson’s test). We were unable to
observe signiﬁcant cross-resistance (represented by sig-
niﬁcant linear correlation) between ErPC3 and the
established antileukemic agents in the AML samples after
96 h of incubation. The regression coefﬁcient r was –0.03
(P = 0.9) for cytarabine, r = 0.04 (P = 0.9) for idarubicine
and r = 0.2 (P = 0.5) for etoposide.
Interaction analysis in HL 60 cell line
As it is unknown whether ErPC3 and cytarabine, etoposide
and idarubicine are mutually exclusive or nonexclusive in
Fig. 3 Representative FACS
analysis of apoptosis by ErPC3
in HL 60 cells. Upper line: Dot
blots of Annexin V/7-AAD
staining (a endogenous, b after
exposure to ErPC3). Lower line:
Histogram blots of active
caspase 3 staining (c
endogenous, d after exposure to
ErPC3)
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alternatives (a = 0 and a = 1). For calculation of the mean
CI, it was calculated individually for each experiment and
from the resulting CIs the mean was calculated. The results
are given in Table 1. For cytarabine, additive interactions
can be assumed with a minimum mean value of CI of 1.0
(for a = 0 after 24 h) and a maximum mean value of 1.5
(for a = 1 after 72 h). For etoposide mean values ranged
between 1.2 (for a = 0 after 24 h) and 1.8 (for a = 1 after
72 h), indicating (sub-)additivity. However, the combina-
tion of idarubicine with ErPC3 resulted in much higher
mean values with 1.6 (for a = 0 after 24 h) and 5.6 (for
a = 1 after 72 h), respectively. These results imply antag-
onism for the combination of ErPC3 and idarubicine in
HL60 cells.
For the construction of isobolograms, LC 50s and
Modes I, IIa and IIb the mean results of all experiments
were chosen (results after 72-h exposure were chosen for
better accuracy). The data points (dots) for combinations of
each experiment are shown individually in Fig. 4a–c
together with the mean value of all combinations (dia-
monds). The isobologram ﬁndings are consistent with the
results of the respective combination index analysis. For
cytarabine and etoposide (Fig. 4a, b) the individual out-
comes (two supraadditive and one subadditive and
antagonistic, respectively) accumulate in an additive mean
which projects right into the envelope of additivity in both
series. For idarubicine (Fig. 4c), two additive and one
antagonistic sample add up to an antagonistic mean value
which accordingly falls into the area of protection.
Interaction analysis in patient samples
For calculation of the CI, each individual CI from the
respective experiment was calculated and the median CI
was assessed. The results of each combination of ErPC3
with cytarabine, etoposide and idarubicin are also given in
Table 1. For the ErPC3–cytarabine combination, median
values ranged between 0.7 (for a = 0 after 24 h) and 1.6
(for a = 1 after 96 h) and therefore predict an additive
effect. The similar result can be assumed for the combi-
nation of ErPC3 and etoposide with median values of 1.0
(for a = 0 after 24 h) and 1.3 (for a = 1 after 24 h). The
results for the ErPC3–idarubicine combination with med-
ian values of 1.1 (for a = 0 after 24 h) and 2.3 (for a =1
after 24 h) predict a (sub-)additive outcome.
To construct an isobologram for analysis of the different
patient samples, we chose the median values of the dif-
ferent LCs (LC 10–LC 50) obtained in the experiments
after 96-h exposure to assess LC 50s, Mode I, IIa and IIb.
The individual data points of combinations for each indi-
vidual experiment were then drawn separately into the
graph as dots with the median of all results depicted as
diamond. The respective isobologram analysis are given in
Fig. 4d–f. Figure 4d shows the result for ErPC3 and cyt-
arabine. Most of the data points together with the median
value project under the envelope of additivity and therefore
indicate supraadditivity. For etoposide (Fig. 4e) the median
value falls into the envelope of additivity, although coor-
dinates of several data points projects also into the area of
protection. Results of both analyses are in line with the
results of combination indices. In contrast, for idarubicine
and ErPC3, the result of the isobologram analysis implies
mutual supraaddivity in patient samples, as the median
value drops below the envelope of additivity (Fig. 4f)
despite several data points projecting into the area of
protection.
Discussion
The presented data show that ErPC3 exerts a high anti-
leukemic activity in an AML cell line and also in freshly
collected samples from patients with AML. LC 50s as a
surrogate marker for the cell killing potential was 7.0 lg/
ml (13.9 lM) and 3.2 lg/ml (6.4 lM) after 24 and 72 h
exposure in HL 60 cells and 30.1 lg/ml (59.8 lM) after
24 h and 8.6 lg/ml (17.1 lM) after 96 h in patient sam-
ples. From these data, the concentration coefﬁcient N for
ErPC3 can be determined as 1.9 for HL 60 cells and 1.2 for
patient samples, therefore being close to 1 in both settings.
Concluding from our experience of ex vivo drug mea-
surement in AML [4, 6] exposure concentration as well as
exposure time is (almost) equally important for this drug in
Table 1 Results of interactions analysis in HL 60 cells and patient
samples
HL 60 cell Patient samples
24 h 72 h 24 h 96 h
a =0 a =1 a =0 a =1 a =0 a =1 a =0 a =1
ErPC3—cytarabine
Mean 1.0 1.3 1.1 1.5 1.0 1.2 1.6 2.1
Median 0.8 0.9 1.2 1.5 0.7 0.8 0.9 1.6
ErPC3—etoposide
Mean 1.2 1.4 1.3 1.8 1.2 1.4 1.2 1.4
Median 1.1 1.3 1.6 2.0 1.0 1.3 1.0 1.2
ErPC3—idarubicine
Mean 1.6 2.2 3.5 5.6 1.1 1.2 1.5 2.0
Median 1.5 2.1 2.1 3.0 1.1 2.3 1.4 1.6
Values given are after 72–96 h exposure to the respective combina-
tion. Values *1 are considered additive, \1 synergistic and values
[1 antagonistic
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account, the determined LC 50 for HL 60 cells in our study
is higher than in previous studies that found the IC 50 for
HL 60 cells to be 1.54 lM[ 7]. The ﬁnding of an even
higher LC 50 for ErPC3 in patient samples of 59.8 lM
stresses the relevance of in-vitro drug testing in fresh
samples instead of model cell lines. A detailed pharma-
cokinetic analysis of ErPC3 is currently performed in the
context of an ongoing phase I clinical study, preliminary
data however show that plasma concentrations of more
than 30 lg/ml ErPC3 can be achieved in humans without
toxicity (personal communication by L. Lindner). The in
vitro analysis of ErPC3 performed in this study gives
reasonable options how modulation of peak plasma con-
centrations can be achieved by adjustment of exposure time
and administered concentration.
The observed decrease of tetrazolium metabolism by
ErPC3 in the WST-1 assay can not be explained by growth
inhibition alone and is therefore not termed IC 50 (inhi-
bition of 50% cell growth). Rather, we were able to show
that ErPC3 signiﬁcantly increased the Annexin V positive
fraction in HL 60 cells by 4.5-fold. The cell death seems to
be executed by apoptosis via activation of caspase 3 whose
activity was doubled after exposure to ErPC3. This ﬁnding
is in line with other experiments that showed classical
apoptotic features of leukemic cell lines as DNA frag-
mentation, cell shrinkage and formation of apoptotic bodies
after exposure to alkylphosphocholines [5, 14]. Interest-
ingly no cross resistance was seen in patient samples
between ErPC3 and cytarabine, etoposide and idarubicine
which implicate a functionally different mode of action of
the alkylphosphocholines. To test their interaction in vitro,
we performed simultaneous exposure of ErPC3 and AraC,
etoposide and idarubicine in HL 60 cells and patient
samples and analyzed the results by CI and isobologram
analysis. The CI was calculated for both a = 0 and a =1 ,
however it seems unlikely that ErPC3 interferes with
nucleoside metabolism or topoisomerase activity and could
therefore considered mutually exclusive in their action. In
HL60 cells the combination of ErPC3 with AraC and
etoposide was additive by CI and isobologram analysis. For
idarubicine, CI after 72 h suggested antagonism (especially
for a = 1), as well as isobologram analysis. In patient
samples these results were consistent except for idarubicine
which was found to be (sub-)additive by CI and supraad-
ditive by isobologram analysis. The reason for these
different results remains unclear, however in respect of
possible clinical applications, the outcome in fresh patients
samples seems more relevant than those in AML models.
With caution, it can therefore be concluded that these drugs
augment each other in an additive way.
The question of ‘‘synergy’’ (i.e., supra-additivity)
between ErPC3 and the other antileukemic agents may
therefore be answered with ‘‘no’’; however the deﬁnition
Fig. 4 Isobologram analysis of ErPC3 and AraC, etoposide and
idarubicine interaction in HL 60 (upper line) and patient samples
(lower line). The grey area surrounded by Mode I, IIa and IIb
represents the ‘‘envelope of additivity’’. Dots represent individual
experiments. Dots that fall outside the depicted area are marked with
their coordinates. Diamonds represent mean value (in HL 60) and
median value (in patient samples). For detailed description please
refer to text
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more) drugs than the predicted effect of combined agents
is far too simple. According to W. Greco, ‘‘the main
rationale for combining anticancer agents (which are also
effective individually) in the clinic is that by combining
agents with non-overlapping toxic effects, more total
tumor-killing poisons can be applied without increasing
the overall toxicity to the host beyond acceptable limits’’
[8]. Especially in this context, alkylphosphocholines seem
an attractive combination partner in the treatment of
leukemias, as they are lacking myelosuppression as the
major side effect of all other antileukemic agents. Rather,
treatment with HePC results in an increase in leukocyte
and thrombocyte count with a maximum effect of up to
20 G/l leucocytes and 700 G/l thrombocytes after 4 weeks
[21, 22]. This clinical ﬁnding was conﬁrmed by the
observation of co-stimulatory effects of HePC on granu-
lopoesis [28] and thrombopoesis by increased synthesis
and excretion of interleukin-6, thrombopoetin and granu-
locyte-macrophage colony-stimulating factor in vitro [3].
ErPC3 may feature similar effects but this has to be
conﬁrmed in man; however whether it stimulates myelo-
poiesis or just not compromises it remains almost alike,
as in both cases the agent would render an ideal combi-
nation partner in highly myelotoxic polychemotherapy
regimens applied to patients with an already insufﬁcient
hematopoiesis.
In conclusion, erufosine possess a high antileukemic
activity in AML in vitro in both cell lines and patient
samples by induction of apoptosis and acts additive to
antileukemic drugs used in induction and consolidation
therapy. This together with a (probable) attractive panel of
side effects warrants further clinical studies of this drug in
AML. The results of the ongoing phase I clinical trial of
erufosine should be interesting with respect to future phase
II studies with potential combinations partners for ErPC3
which have ﬁrst been characterized in this study.
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